ATE309800T1 - Verwendung einer kombinationszusammensetzung bestehend aus propionyl l-carnitin und weiteren wirkstoffen zur behandlung der erektilen dysfunktion - Google Patents

Verwendung einer kombinationszusammensetzung bestehend aus propionyl l-carnitin und weiteren wirkstoffen zur behandlung der erektilen dysfunktion

Info

Publication number
ATE309800T1
ATE309800T1 AT02804338T AT02804338T ATE309800T1 AT E309800 T1 ATE309800 T1 AT E309800T1 AT 02804338 T AT02804338 T AT 02804338T AT 02804338 T AT02804338 T AT 02804338T AT E309800 T1 ATE309800 T1 AT E309800T1
Authority
AT
Austria
Prior art keywords
carnitine
propionyl
treatment
erectile dysfunction
active ingredients
Prior art date
Application number
AT02804338T
Other languages
German (de)
English (en)
Inventor
A Koverech
A Serv Lenzi
Umberto I Policlinico
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE309800T1 publication Critical patent/ATE309800T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02804338T 2001-12-04 2002-12-04 Verwendung einer kombinationszusammensetzung bestehend aus propionyl l-carnitin und weiteren wirkstoffen zur behandlung der erektilen dysfunktion ATE309800T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
PCT/IT2002/000758 WO2003047563A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Publications (1)

Publication Number Publication Date
ATE309800T1 true ATE309800T1 (de) 2005-12-15

Family

ID=11455907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804338T ATE309800T1 (de) 2001-12-04 2002-12-04 Verwendung einer kombinationszusammensetzung bestehend aus propionyl l-carnitin und weiteren wirkstoffen zur behandlung der erektilen dysfunktion

Country Status (16)

Country Link
US (3) US20050080018A1 (enExample)
EP (1) EP1450782B9 (enExample)
JP (1) JP4370169B2 (enExample)
KR (1) KR100907938B1 (enExample)
AT (1) ATE309800T1 (enExample)
AU (1) AU2002365847A1 (enExample)
CA (1) CA2465471C (enExample)
DE (1) DE60207442T2 (enExample)
DK (1) DK1450782T3 (enExample)
ES (1) ES2250749T3 (enExample)
HU (1) HU229214B1 (enExample)
IT (1) ITRM20010708A1 (enExample)
MX (1) MXPA04005269A (enExample)
PL (1) PL211211B1 (enExample)
SI (1) SI1450782T1 (enExample)
WO (1) WO2003047563A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040561A1 (it) 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR20110118668A (ko) 2009-02-13 2011-10-31 베링거 인겔하임 인터내셔날 게엠베하 1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt­2 억제제
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
US20180104268A1 (en) * 2015-04-30 2018-04-19 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
WO2018087132A1 (en) 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
EP0793962B1 (en) * 1996-03-04 1999-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Medicament containing a carnitine derivative for treating arteriosclerosis obliterans
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
IT1293539B1 (it) * 1997-07-16 1999-03-01 Sigma Tau Ind Farmaceuti Composizione nutritiva per soggetti in stato di debilitazione causato da stress
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6241471B1 (en) * 1999-08-26 2001-06-05 General Electric Co. Turbine bucket tip shroud reinforcement
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di

Also Published As

Publication number Publication date
SI1450782T1 (sl) 2006-02-28
EP1450782B1 (en) 2005-11-16
JP2005511655A (ja) 2005-04-28
DE60207442T2 (de) 2006-07-27
US20070117762A1 (en) 2007-05-24
MXPA04005269A (es) 2004-10-11
ES2250749T3 (es) 2006-04-16
ITRM20010708A1 (it) 2003-06-04
US20050080018A1 (en) 2005-04-14
CA2465471C (en) 2010-10-19
US20120041005A1 (en) 2012-02-16
KR100907938B1 (ko) 2009-07-16
KR20050044594A (ko) 2005-05-12
HU229214B1 (hu) 2013-09-30
WO2003047563A1 (en) 2003-06-12
EP1450782A1 (en) 2004-09-01
DE60207442D1 (de) 2005-12-22
ITRM20010708A0 (it) 2001-12-04
PL371131A1 (en) 2005-06-13
HUP0402062A3 (en) 2012-09-28
JP4370169B2 (ja) 2009-11-25
CA2465471A1 (en) 2003-06-12
PL211211B1 (pl) 2012-04-30
HUP0402062A2 (hu) 2005-02-28
AU2002365847A1 (en) 2003-06-17
US8343979B2 (en) 2013-01-01
DK1450782T3 (da) 2006-02-20
EP1450782B9 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
TW200724033A (en) Anthranilamide arthropodicide treatment
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
PT1796660T (pt) Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
MXPA02011288A (es) Tioacetamidas substituidas.
DOP2002000447A (es) 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60207442D1 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MY148459A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE212841T1 (de) Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
ATE328602T1 (de) Kombinationspräparat zur behandlung des diabetes mellitus
SE0102185D0 (sv) New subject-matter
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE340569T1 (de) Verwendung eines neuen mittels zur verhütung von infektionen
NO20052379D0 (no) Nye antitumorale forbindelser
DE60203882D1 (de) Verwendung von 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol zur behandlung von harninkontinenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1450782

Country of ref document: EP